ReviewCells2023
A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Circulating miRNAs for glioblastoma monitoring: from biofluid to clinical decision.Molecular therapy. Oncology · 2026Review
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- Article
- Exercise-associated microRNA programs as candidate modulators and biomarkers in glioblastoma: a narrative review.Discover oncology · 2026Review
- MicroRNAs as diagnostic prognostic and therapeutic biomarkers in glioblastoma.Discover oncology · 2026Review
- Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens.Diagnostics (Basel, Switzerland) · 2026Article
- Invasiveness-related microRNA expression in glioma: associations with clinical outcomes, tumor burden, and health-related quality of life.Cancer cell international · 2026Article
- Review
- Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy.Medical oncology (Northwood, London, England) · 2025Review
- Mechanistic insights into CDCA gene family-mediated glioblastoma progression: implications for diagnosis, prognosis, and therapeutic targeting.Hereditas · 2025Article
- The Clinical Role of miRNAs in the Development and Treatment of Glioblastoma.International journal of molecular sciences · 2025Review
- Unveiling cell-type-specific microRNA networks through alternative polyadenylation in glioblastoma.BMC biology · 2025Article
- Exploring microRNA targeting as a promising approach for solid tumor treatment.Frontiers in oncology · 2025Review
- Unlocking the Potential of Circulating miRNAs as Biomarkers in Glioblastoma.Life (Basel, Switzerland) · 2024Review
- METTL14-mediated m6A mRNA modification of G6PD promotes lung adenocarcinoma.Cell death discovery · 2024Article
- Review
- mAmerican journal of cancer research · 2024Article
- Article
- Application of Fast Integration Strategy for Multi-Omics Data and Limited Random Forest Model in Survival Prediction of Glioblastoma.IET systems biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is the most aggressive form of brain tumor originating from glial cells with a maximum life expectancy of 14.6 months. Despite the establishment of multiple promising therapies, the clinical outcome of glioblastoma patients is abysmal. Drug resistance has been identified as a major factor contributing to the failure of current multimodal therapy. Epigenetic modification, especially DNA methylation has been identified as a major regulatory mechanism behind glioblastoma progression. In addition, miRNAs, a class of non-coding RNA, have been found to play a role in the regulation as well as in the diagnosis of glioblastoma. The relationship between epigenetics, drug resistance, and glioblastoma progression has been clearly demonstrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.